Overview

Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

Status:
Enrolling by invitation
Trial end date:
2026-12-30
Target enrollment:
0
Participant gender:
All
Summary
This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Alumis Inc
Criteria
Inclusion Criteria:

- Must have completed a prior ESK-001 study

- Men and Women must use highly effective methods of contraception for the entirety of
the study

Exclusion Criteria:

- Pregnancy

- Received a prohibited concomitant medication